logo
Share SHARE
FONT-SIZE Plus   Neg

ADTRAN Revises Q1 Forecast - Quick Facts

ADTRAN, Inc. (ADTN) said it now expects first-quarter earnings per share to range from $0.17 to $0.20. Non-GAAP earnings per share for the quarter are expected to range from $0.22 to $0.25.

Revenue for the first quarter is currently expected to range from $130 million to $135 million.

ADTRAN chief executive officer Tom Stanton, said, "Two issues impacted us in the first quarter. The first was a slower than normal start to the seasonal buying pattern at some of our carrier customers. The second, which had a greater impact, was a delay in both the start and ramp of orders from a carrier customer due to new system implementations. Order rates for the month of March have substantially improved and we are encouraged that the prior slowdown that we experienced is behind us."

ADTRAN noted that acquisition related expenses, amortizations and adjustments related to the acquisition of Bluesocket, Inc. and the planned acquisition of the NSN Broadband Access business is estimated to reduce earnings per share by $0.02 for the first quarter 2012. Stock-based compensation expense is estimated to reduce earnings per share by $0.03 for quarter, the company added.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The holiday throng seeking to take a flight out to their preferred destinations at the at New York's Kennedy International Airport ahead of the Memorial Day holiday were in for a rude shock. Technology played a spoilsport, as a computer system broke down Sunday evening at a terminal, causing flight delays and cancellations that resulted in manual check-in process for thousands of holiday passeng The month of May saw the FDA greenlight 5 new drugs, including 1 new molecular entity, and surprisingly turn down 1 drug candidate, whose approval was considered a no-brainer by some experts. Lab equipment maker Thermo Fisher Scientific Inc. has agreed to acquire electron microscope maker FEI Co. for about $4.2 billion in cash, the two companies said Friday. Thermo Fisher noted that FEI's electron microscopy platform will complement its own mass spectrometry systems to accelerate advancements in structural biology.
comments powered by Disqus
Follow RTT